Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. M. Abraham (Miami Beach, United States of America), William Abraham, Juan Sabater, Tahir Ahmed. Allosteric inhibition of the cystic fibrosis transmembrane conductance regulator (CFTR) slows airway mucus transport in normal sheep. Eur Respir J 2015; 46: Suppl. 59, 2054

Member's Comments

No comment yet.

Related content which might interest you: Cystic fibrosis transmembrane conductance regulator pharmacotherapy Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=88 Year: 2006 Pharmacology and regulation of ENaC function: implication in cystic fibrosis Source: Annual Congress 2009 - Novel regulators of alveolar liquid clearance Year: 2009 A three miRNA signature regulates the CF transmembrane conductance regulator (CFTR) in cystic fibrosis airway epithelium Source: Annual Congress 2011 - Epithelial cells: role in health and disease Year: 2011 Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration Source: Eur Respir J, 59 (2) 2100185; 10.1183/13993003.00185-2021 Year: 2022 Channelopathies in bronchiectasis Source: Eur Respir Mon 2011; 52: 150-162 Year: 2011 Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013 Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator (CFTR) ion transport Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 The cystic fibrosis transmembrane conductance regulator and its modulators: clinical implications Source: Virtual Congress 2020 – Respiratory infections Year: 2020 Expression and function of cystic fibrosis transmembrane conductance regulator in rat intrapulmonary arteries Source: Eur Respir J 2007; 30: 857-864 Year: 2007 How organoids helped to discover cystic fibrosis transmembrane conductance regulator (CFTR) therapeutics and predict response to treatment Source: International Congress 2016 – Closing the gap: novel translational research strategies Year: 2016 Pharmacological treatment of the biochemical defect in cystic fibrosis airways Source: Eur Respir J 2001; 17: 1314-1321 Year: 2001 Cystic fibrosis transmembrane conductance regulator and sphingolipids regulate hypoxic pulmonary vasoconstriction Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 The potential interaction of MARCKS-related peptide and diltiazem on acrolin-induced airway mucus hypersecretion in rats Source: Annual Congress 2013 –Stress responses and T-cell behaviour in the lung Year: 2013 LATE-BREAKING ABSTRACT: Reducing inflammation in the lung by targeting the endothelial cystic fibrosis transmembrane conductance regulator with copper-tobramycin Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 TRPV4 and activation of airway sensory nerves: The role of ATP Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015 ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020 Type II transmembrane serine protease matriptase is a mediator of pulmonary fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Transient receptor potential channels in a mouse model of isocyanate-induced airway hyperresponsiveness Source: International Congress 2014 – Mechanistic murine studies of asthma and lung inflammation Year: 2014 The cystic fibrosis transmembrane conductance regulator: state of the art Source: Breathe 2008; 5: 163-167 Year: 2008